Poor
Misaligned
Patient Risk:
Moderate
Summary
Several claims are either not supported or incorrectly attributed. While Vascepa indications and triglyceride lowering are generally aligned, most combination-risk claims (bleeding/bleeding time, kidney damage, liver damage, liver enzymes, GI/headache/fatigue) are not supported for the specific combination with bile acid sequestrants, and the bile acid sequestrant mechanism claims are not evaluated against any provided bile-acid-sequestrant label content.
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in the blood.
Section 1 (indicated as adjunct to diet to reduce TG levels in adults with severe hypertriglyceridemia) and Section 12.2/12.1 (TG reduction described).
Vascepa is effective at reducing triglyceride levels.
Section 12.2 (4 grams/day reduced median TG from baseline relative to placebo in severe hypertriglyceridemia; also indicated in Section 14.2 that VASCEPA reduced median TG, VLDL-C, and Apo B from baseline vs placebo).
Vascepa may help prevent cardiovascular disease by reducing triglyceride levels.
Section 1 (reduced risk of MI, stroke, coronary revascularization, and unstable angina hospitalization in adults with elevated TG on statin therapy) and Section 14.1 (reduced risk of cardiovascular endpoints). Note: label does not state the mechanism is specifically “by reducing triglyceride levels.”
The combination of Vascepa and bile acid sequestrants may increase the risk of bleeding.
Partial/indirect support only: Section 5.3 (bleeding risk with VASCEPA; greater with concomitant antithrombotic medications) and Section 7.1 (monitor bleeding with concomitant anticoagulants and/or antiplatelet agents). No label support specifically for bile acid sequestrants as the concomitant drug.
Unsupported Statements
The combination of Vascepa and bile acid sequestrants may increase the risk of kidney damage.
No provided Vascepa label content links kidney damage to VASCEPA and no provided interaction/precaution content addresses this combination.
The combination of Vascepa and bile acid sequestrants may increase the levels of other medications in the blood.
No provided Vascepa label content supports increased levels of other medications with bile acid sequestrants.
The combination of Vascepa and bile acid sequestrants may be associated with gastrointestinal side effects.
No provided Vascepa label content supports this statement for the specific combination with bile acid sequestrants.
The combination of Vascepa and bile acid sequestrants may be associated with headaches.
No provided Vascepa label content supports headaches for VASCEPA, and nothing links headaches to the combination with bile acid sequestrants.
The combination of Vascepa and bile acid sequestrants may be associated with fatigue.
No provided Vascepa label content supports fatigue for the combination with bile acid sequestrants.
The combination of Vascepa and bile acid sequestrants may increase bleeding time.
Section 7.1 mentions prolongation of bleeding time in published studies with omega-3 fatty acids, but no provided label content supports that this occurs specifically with the combination of VASCEPA + bile acid sequestrants.
The combination of Vascepa and bile acid sequestrants may increase the risk of liver damage.
No provided Vascepa label content states or implies liver damage risk with this combination.
The combination of Vascepa and bile acid sequestrants may increase the liver enzymes.
While hepatic impairment monitoring is described (Section 8.7), no provided label content supports increased liver enzymes specifically due to the combination with bile acid sequestrants.
The combination of Vascepa and bile acid sequestrants may increase the risk of interactions with other medications.
No provided label content supports this for bile acid sequestrants specifically.
The combination of Vascepa and bile acid sequestrants may increase the risk of adverse events.
No provided label content supports this for the specific combination.
The combination of Vascepa and bile acid sequestrants may increase the number of adverse events reported by patients.
No provided label content supports this for the specific combination.
The combination of Vascepa and bile acid sequestrants may increase bleeding time.
No provided label content supports this for the specific combination.
Contradictions
Important Omissions
Cardiovascular risk reduction claim is not qualified as an indication: label specifies adjunct to maximally tolerated statin therapy (and diet) with specific patient populations and outcomes; it does not state “prevent cardiovascular disease by reducing triglyceride levels” as the basis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several combination-safety claims (kidney damage, liver damage/enzymes, GI/headache/fatigue, increased interaction potential and other drug levels) are not supported by the provided VASCEPA prescribing information excerpts for VASCEPA + bile acid sequestrants.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Many claims about the specific combination of VASCEPA with bile acid sequestrants (bleeding time, kidney/liver injury, increased liver enzymes, GI/headache/fatigue, increased levels of other medications) are unsupported by the provided FDA label excerpts.
Suggested Improvement
Limit safety/interaction statements to those supported by the provided VASCEPA label sections (notably bleeding risk and monitoring with concomitant anticoagulants/antiplatelet agents, AF/flutter warning, and hepatic impairment monitoring), and avoid attributing unlabelled combination-specific risks to bile acid sequestrants. For cardiovascular benefit, align wording to the labeled indications/outcomes and patient populations rather than implying TG reduction is the sole mechanism.